 DUBLIN, Ireland, Nov. 04, 2020 GLOBE NEWSWIRE -- Prothena Corporation plc NASDAQ:PRTA, a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced that it will present preclinical data from two programs in its Alzheimers disease portfolio at the 13th Clinical Trials on Alzheimers Disease Conference 2020 CTAD 2020. Prothenas programs being highlighted at CTAD 2020 are next generation anti-Aβ antibodies for subcutaneous administration to improve patient access, and a multi-immunogen vaccine that targets key Aβ and tau epitopes, the two main pathological proteins involved in the cause and progression of Alzheimers disease, for the prevention and treatment of Alzheimers Disease. The two programs are part of Prothenas Alzheimers disease portfolio that includes antibodies, vaccines and small molecules. 